Published in Medicine and Law Weekly, June 1st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at NEUROCHEM INC..
Report 1: Neurochem (International) Limited (Neurochem), a wholly owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that it received notification from the United States Food and Drug Administration (FDA) that the action date for FDA's review of the New Drug Application (NDA) for eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis, has been extended to July 16, 2007. Previously, the action date under the Prescription Drug User Fee...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly